Steris (STE) Cash & Equivalents (2017 - 2026)

Steris has reported Cash & Equivalents for 10 years, with the latest figure at $482.3 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 72.43% year-over-year to $482.3 million in Q2 2026; TTM through Jun 2026 was $482.3 million, a 72.43% increase from a year earlier, with the FY2026 full-year figure at $439.6 million, up 156.03% from the prior year.
• Cash & Equivalents was $482.3 million for Q2 2026 at Steris, up from $439.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $482.3 million in Q2 2026, with the low at $155.2 million in Q4 2024.
• Average Cash & Equivalents over 5 years is $269.9 million, with a median of $236.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents tumbled 40.85% in 2022, then soared 173.04% in 2025.
• Over 5 years, Cash & Equivalents stood at $259.4 million in 2022, then declined by 24.59% to $195.6 million in 2023, then declined by 20.66% to $155.2 million in 2024, then soared by 173.04% to $423.7 million in 2025, then climbed by 13.83% to $482.3 million in 2026.
• The last three Cash & Equivalents figures came in at $482.3 million (Q2 2026), $439.6 million (Q1 2026), and $423.7 million (Q4 2025), per Business Quant data.